Oppenheimer raised the firm’s price target on Madrigal Pharmaceuticals to $320 from $300 and keeps an Outperform rating on the shares following the Q4 results. The firm is encouraged by several potentially transformative events, including the priority review setting up resmetirom as potentially the first FDA-approved nonalcoholic steatohepatitis therapy, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals appoints Mardi Dier as CFO
- Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- Madrigal Pharmaceuticals reports Q4 EPS ($5.68), consensus ($5.28)
- Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
- Madrigal opportunity in MASH remains after Boehringer data, says UBS